Krabbe Disease
https://www.nature.com/articles/s41598-024-82927-1#
Krabbe disease (KD) is a rare and inherited disorder that affects the nervous system. It is caused by a lack of a crucial enzyme called galactosylceramidase (GALC), which leads to the build-up of a toxic substance known as psychosine. This accumulation damages the cells that produce myelin—the protective coating around nerves—leading to severe neurodegeneration and causes severe inflammation in the brain and spinal cord. Most patients with KD are infants who experience rapid neurological decline and often do not survive past early childhood. In this study, the researchers investigated whether the protein lipocalin-2 (LCN2), which is often elevated during inflammation in the brain, plays a role in worsening KD. Using a mouse model of KD, it was found that levels of LCN2 were significantly increased in the brain, especially in cells called astrocytes that respond to injury or stress. To test its impact, they bred mice that lacked both GALC and LCN2. While removing LCN2 did not change psychosine levels or dramatically extend life, it did reduce inflammation in the brain, slightly delay disease progression and improve motor function. These results suggest that LCN2 is not a direct cause of Krabbe disease but acts to intensify the brain’s inflammatory response, contributing to symptom severity. Importantly, reducing LCN2 helped calm this inflammation without causing side effects or triggering other related genes. Although targeting LCN2 alone isn’t a cure, it may be useful in combination with other treatments—like gene or stem cell therapy—to improve quality of life. Because LCN2 is also elevated in other neurological diseases, this discovery may have broader implications beyond KD, offering hope for future therapies aimed at reducing harmful brain inflammation.